Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
US Stock Futures Signal Lower Start On Wall Street
The 5 Biggest Biotech Stocks
How To Trade Stocks: Shaken Out? You Can Get Back In (Investor's Business Daily)
Related SNY
US Stock Futures Signal Lower Start On Wall Street
10 Biotech Stories You Might've Missed This Week
Franchise Fortunes Mark Shifts In Consensus For Marketed Products (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers


Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters